INM (InMed Pharmaceuticals Inc. Common Shares) stock: $1.42, $7.8M market cap, $2.2M cash, $5.6M EV, $8.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$1.42
Market cap
$7.8M
Cash
$2.2M
Enterprise value
$5.6M
Balance sheet
Cash
$2.2M
Debt
$0.0M
Net cash
$2.2M
Enterprise value
$5.6M
Basic shares
5.3M shares
Fully diluted shares
5.7M shares
Fully diluted market cap
$8.0M
Cash per share
$0.41
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading INM daily closes…
Loading price history…
Pipeline assets
INM-901
Preclinical · ActiveModality: small molecule (preferential signaling agonist)
Target CB1/CB2 (also impacts PPAR signaling)
Indications
Alzheimer's disease(Preclinical)
Catalysts
— Q3 2026
— 2027
Status note Disease-modifying candidate with IND-enabling pharmacology and toxicology studies underway.
INM-089
Preclinical · ActiveModality: small molecule
Target CB1/CB2
Indications
Dry age-related macular degeneration(Preclinical)
Catalysts
— Early 2027
Status note Preclinical program for dry AMD.
INM-755 (cannabinol)
Stage not disclosed · ActiveModality: topical cream
Target CB1/CB2
Indications
Epidermolysis bullosa(Stage not disclosed)
Status note Cannabinol cream. Company does not currently intend to devote significant resources to advancing it; further development would require additional financing.
Per-asset detail extracted from the 10-Q filed 2026-05-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
800,000
+800,000
0.06%
2026-08-14
Ikarian Capital
245,025
+245,025
0.06%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.